Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiona M Ross

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Blood|November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCharlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|July 10, 2010
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic valueBrian A Walker, Paola E Leone, Laura Chiecchio, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|July 5, 2007
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myelomaMatthew W Jenner, Paola E Leone, Brian A Walker, et al.
The Lancet. Oncology|July 21, 2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialGareth J Morgan, J Anthony Child, Walter M Gregory, et al.
Genes, Chromosomes & Cancer|October 8, 2014
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myelomaEileen M Boyle, Paula Z Proszek, Martin F Kaiser, et al.
British Journal of Haematology|March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study resultsGraham H Jackson, Gareth J Morgan, Faith E Davies, et al.
Nature Genetics|November 29, 2011
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma riskPeter Broderick, Daniel Chubb, David C Johnson, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Blood|November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCharlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|July 10, 2010
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic valueBrian A Walker, Paola E Leone, Laura Chiecchio, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|July 5, 2007
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myelomaMatthew W Jenner, Paola E Leone, Brian A Walker, et al.
The Lancet. Oncology|July 21, 2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialGareth J Morgan, J Anthony Child, Walter M Gregory, et al.
Genes, Chromosomes & Cancer|October 8, 2014
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myelomaEileen M Boyle, Paula Z Proszek, Martin F Kaiser, et al.
British Journal of Haematology|March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study resultsGraham H Jackson, Gareth J Morgan, Faith E Davies, et al.
Nature Genetics|November 29, 2011
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma riskPeter Broderick, Daniel Chubb, David C Johnson, et al.
Pageof 6